Optimi Health meldet Beginn der ersten MDMA-gestützten Behandlungen im Jahr 2026 in einem erweiterten Netzwerk australischer Kliniken
Vancouver, British Columbia--(Newsfile Corp. - Montag, 16. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller pharmazeutischer psychedelischer Arzneimittelprodukte, gab heute bekannt, dass die ersten Patientinnen und Patienten des Jahres 2026 in autorisierten Kliniken in ganz Australien mit den MDMA-Kapseln des Unternehmens behandelt wurden. Die Behandlungen erfolgen im Rahmen des Authorise
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-16 1:00 AM EST | Optimi Health Corp.
Restart Life Sciences Executes Definitive Agreement to Acquire Holy Crap Foods
Vancouver, British Columbia--(Newsfile Corp. - February 13, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that, further to its news release dated December 22, 2025, it has entered into a share purchase agreement (the "Definitive Agreement") among Holy Crap Foods Inc. ("Holy Crap") and Happy Belly Coffee Inc. (the "Vendor"), a subsidiary of Happy Belly Food Group Inc. (CSE: HBFG) that owns all of the issue
Technology, Biotechnology, Health
2026-02-13 10:10 AM EST | Restart Life Sciences Corp.
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - February 11, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third fiscal quarter ended December 31, 2025 (the company's fiscal Q3 2026). All dollar amounts in this press release are in US dollars unless specified otherwise. Key update on GRAFAPEX Medexus has continued to see a positive market response to GR
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-11 5:30 PM EST | Medexus Pharmaceuticals Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026
Northvale, New Jersey--(Newsfile Corp. - February 11, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2026 fiscal year will be released on Tuesday, February 17, 2026. Elite's management will host a live conference call on Wednesday, February 18th, at 11:30 AM EST to discuss the company's financial and operating
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-11 4:30 PM EST | Elite Pharmaceuticals, Inc.
Rapid Dose Therapeutics Begins Trading on the OTCQB in the United States Under Symbol RDTCF, Expanding Access for U.S. Healthcare and Biotechnology Investors
Burlington, Ontario--(Newsfile Corp. - February 11, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company revolutionizing drug delivery through innovation, today announced that its common shares are now trading in the United States on the OTCQB Venture Market under the ticker symbol RDTCF. The OTCQB listing expands Rapid Dose Therapeutics' presence in the U.S. capital markets by increasing accessibili
2026-02-11 11:21 AM EST | Rapid Dose Therapeutics Corp.
Tersis Technologies Welcomes Daniel "Jack" Gaido, Jr. to Its Board of Directors
Brooksville, Florida--(Newsfile Corp. - February 11, 2026) - Tersis Technologies, Inc. (OTCID: TERS) a systems-focused energy and infrastructure company advancing regenerative solutions through practical integration, today announced the appointment of Daniel "Jack" Gaido, Jr. to its Board of Directors.
Agriculture, Energy, Alternative Energy, Health
2026-02-11 10:03 AM EST | Tersis Technologies Inc.
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
Ontario and Haifa, Israel--(Newsfile Corp. - February 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced results from an independent proteomic analysis conducted at the Technion - Israel Institute of Technology. which evaluated multiple production batches of NurExone's exosomes. The results
Biotechnology, Pharmaceuticals, Health
2026-02-10 4:03 PM EST | NurExone Biologic Inc.
Apollo Biowellness Executes Letter Of Intent with Medwell AI, Inc.
North Bergen, New Jersey--(Newsfile Corp. - February 10, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company) is pleased to announce the signing of a Letter of Intent ("LOI") to create a vertically integrated health, wellness and longevity platform.
Household / Consumer / Cosmetics, Health
2026-02-10 9:30 AM EST | Apollo Biowellness, Inc.
Mobile-health Network Solutions Launches Otter.SG, an AI-Powered Clinic Operating System for Hybrid Care
Singapore, Singapore--(Newsfile Corp. - February 10, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI HealthTech platform, today announced the global launch, effective immediately, of Otter.SG, an AI-powered SaaS clinic management platform that unifies clinical, operational, and financial workflows in a single system. Unlike traditional healthcare practice management systems that typically focus on scheduling or billing
2026-02-10 8:41 AM EST | Mobile-health Network Solutions
Aleen Inc. Insights: What Are AI Agents and How They Fit Into Digital Wellness
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, shares an educational overview of AI agents — what they are, how they function, and why they are becoming an important area of exploration within digital products focused on user interaction and insight delivery. AI agents are software-based systems designed to perform defined tasks autonomously or semi-autonomously within digital environments. Unlike static
2026-02-10 8:00 AM EST | Aleen Inc.
Beckett's Launches in BevMo! Stores Across California
Ontario and Los Angeles, California--(Newsfile Corp. - February 10, 2026) - Beckett's Inc. (CSE: BKTS), a fast-growing non-alcoholic beverage brand, announced today that its ready-to-drink non-alcoholic cocktails are rolling out at BevMo! locations across California. The initial launch will feature Beckett's Tonics® Non-Alcoholic Gin & Tonic and upon completion of its next production run, be followed by best seller Beckett's Tonics® Non-Alcoholic Moscow Mule. The
Food / Beverages, Cannabis, Health
2026-02-10 7:30 AM EST | Becketts Inc.
Neural Portfolio Company Hanf.com Reports Strong Fiscal 2025 Results with 58% Revenue Growth and Positive Normalized Operating Income
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to report preliminary unaudited financ
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-10 7:30 AM EST | Neural Therapeutics Inc.
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology. The peer-reviewed article reports resu
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-02-10 7:27 AM EST | Cardiol Therapeutics Inc.
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary IN
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-10 7:00 AM EST | Phio Pharmaceuticals Corp.
Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a major clinical milestone for its portfolio company, Inretio. The medical device innovator has successfully completed the first cohort of the First-in-Human (FIH) study for the PREVA™ Neuro-Thrombectomy System, moving
Technology, Biotechnology, Health
2026-02-10 7:00 AM EST | Therma Bright Inc.
Rapid Dose Therapeutics Launches QuickStrip(TM) Medical Cannabis for Patients in Brazil following ANVISA Approval of Sublingual and Buccal Formats for Medical Treatment
Burlington, Ontario--(Newsfile Corp. - February 10, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company") , a Canadian biotechnology company focused on innovative drug delivery solutions, today announced the commercial launch of its Entourage Phytolab co-branded QuickStrip™ medical cannabis oral thin film in Brazil following regulatory approval for both manufacturing and distribution by Brazil's National Health Regulatory Agency (ANVISA). T
2026-02-10 7:00 AM EST | Rapid Dose Therapeutics Corp.
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board ("SAB") meeting held on January 30, 2026, focused on advancing the strategic positioning of Accum® for antibody-drug conjugate ("ADC") applications. The discussion brought together complementary
Biotechnology, Pharmaceuticals, Health
2026-02-10 3:15 AM EST | Defence Therapeutics Inc.
TempraMed Partners with Super-Pharm, Israel's Leading Pharmacy Chain to Commence a National Product Roll Out Strategy
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce the rollout of its products across Super-Pharm, Israel's largest and most prominent pharmacy and health-retail chain, operating nationwide and serving millions of consumers annually.
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-10 3:00 AM EST | TempraMed Technologies Ltd.
Conexeu Sciences Appoints Sonia Thomas as Head of Strategy & Transformation to Accelerate Enterprise Growth and Execution Excellence
Reno, Nevada--(Newsfile Corp. - February 9, 2026) - Conexeu Sciences Inc. ("Conexeu" or the "Company") a biotechnology innovator redefining regenerative medicine through a next-generation extracellular matrix platform, is pleased to announce Sonia Thomas, MBA, as Head of Strategy & Transformation. In her role, Sonia will help define Conexeu's enterprise strategy, shape portfolio priorities, and long-term growth decisions, and lead cross-functional transformation initiatives
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-09 9:00 AM EST | Conexeu Sciences Inc.
Adia Nutrition Inc. Plans to Initiate Four to Five New Clinical Studies in 2026, Including Expansions in Autism and New Rheumatoid Arthritis Research
Winter Park, Florida--(Newsfile Corp. - February 9, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its subsidiary Adia Med, today announced an ambitious expansion of its clinical research pipeline, with plans to launch four to five additional studies throughout 2026. These new initiatives will build on the company's ongoing success in regenerative therapies using Adia Vita (umbilical cord blood-derived stem cells and exosomes).
Healthcare and Hospitals, Health
2026-02-09 8:31 AM EST | Adia Nutrition Inc.